Cargando…
Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020
BACKGROUND: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, follow-up of patients better determines the characteristics of existing regimens. METHODS: We retrospectively evaluated the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Babol University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272962/ https://www.ncbi.nlm.nih.gov/pubmed/35872684 http://dx.doi.org/10.22088/cjim.13.0.173 |
_version_ | 1784744981029715968 |
---|---|
author | Alikhani, Ahmad Ghazaiean, Mobin Ghasemian, Roya Khademloo, Mohammad |
author_facet | Alikhani, Ahmad Ghazaiean, Mobin Ghasemian, Roya Khademloo, Mohammad |
author_sort | Alikhani, Ahmad |
collection | PubMed |
description | BACKGROUND: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, follow-up of patients better determines the characteristics of existing regimens. METHODS: We retrospectively evaluated the demographic, co-morbidities, gastrointestinal (GI) and liver complications of patients at two teaching hospitals from the first of March to the end of July 2020. All patients received one of two recommended regimens including hydroxychloroquine (HCQ) (400 mg BD on the first day and then 200 mg BD) plus atazanavir/ritonavir (ATV) (300/100 mg daily) or HCQ with the same dose plus lopinavir/ritonavir (Kaletra) (400/100 mg BD) for 5-7 days. RESULTS: We chose 170 cases that received 2 different regimens. In group one, 85(57.6% males) patients received Kaletra and HCQ and group two, 85 (55.3% males) patients received ATV and HCQ. The study of hospitalization in both groups showed no difference in more or less than 5 days hospitalization. (P=0.757) Comparison of mortality rates has not shown a significant difference including 19 (22.4%) deaths in group 1 and 15(17.6%) deaths in group 2 (P=0.443). Nausea followed by diarrhea was the most common side effects in group 1. But no side effects were reported in group 2 (P=0.000). Abnormal liver function tests (LFTs) were seen in both groups. CONCLUSION: Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills. |
format | Online Article Text |
id | pubmed-9272962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Babol University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-92729622022-07-22 Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 Alikhani, Ahmad Ghazaiean, Mobin Ghasemian, Roya Khademloo, Mohammad Caspian J Intern Med Original Article BACKGROUND: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, follow-up of patients better determines the characteristics of existing regimens. METHODS: We retrospectively evaluated the demographic, co-morbidities, gastrointestinal (GI) and liver complications of patients at two teaching hospitals from the first of March to the end of July 2020. All patients received one of two recommended regimens including hydroxychloroquine (HCQ) (400 mg BD on the first day and then 200 mg BD) plus atazanavir/ritonavir (ATV) (300/100 mg daily) or HCQ with the same dose plus lopinavir/ritonavir (Kaletra) (400/100 mg BD) for 5-7 days. RESULTS: We chose 170 cases that received 2 different regimens. In group one, 85(57.6% males) patients received Kaletra and HCQ and group two, 85 (55.3% males) patients received ATV and HCQ. The study of hospitalization in both groups showed no difference in more or less than 5 days hospitalization. (P=0.757) Comparison of mortality rates has not shown a significant difference including 19 (22.4%) deaths in group 1 and 15(17.6%) deaths in group 2 (P=0.443). Nausea followed by diarrhea was the most common side effects in group 1. But no side effects were reported in group 2 (P=0.000). Abnormal liver function tests (LFTs) were seen in both groups. CONCLUSION: Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills. Babol University of Medical Sciences 2022 /pmc/articles/PMC9272962/ /pubmed/35872684 http://dx.doi.org/10.22088/cjim.13.0.173 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Alikhani, Ahmad Ghazaiean, Mobin Ghasemian, Roya Khademloo, Mohammad Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title | Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title_full | Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title_fullStr | Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title_full_unstemmed | Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title_short | Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020 |
title_sort | atazanavir versus lopinavir on covid-19 infection: a retrospective protease inhibitors comparative study 2020 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272962/ https://www.ncbi.nlm.nih.gov/pubmed/35872684 http://dx.doi.org/10.22088/cjim.13.0.173 |
work_keys_str_mv | AT alikhaniahmad atazanavirversuslopinavironcovid19infectionaretrospectiveproteaseinhibitorscomparativestudy2020 AT ghazaieanmobin atazanavirversuslopinavironcovid19infectionaretrospectiveproteaseinhibitorscomparativestudy2020 AT ghasemianroya atazanavirversuslopinavironcovid19infectionaretrospectiveproteaseinhibitorscomparativestudy2020 AT khademloomohammad atazanavirversuslopinavironcovid19infectionaretrospectiveproteaseinhibitorscomparativestudy2020 |